MONTREAL, QUEBEC -- (MARKET WIRE) -- January 30, 2007 -- Ambrilia Biopharma Inc.(TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today that Mr. Stephen G. Sudovar, a highly accomplished pharmaceutical executive and current member of Ambrilia’s Board of Directors, has been unanimously elected Chairman of the Board. In connection with this appointment, Dr. Max Link resigned as director and Chairman of the Board. Dr. Link served as a director of Ambrilia since 1999 and as Chairman of the Board since May 2005. Ambrilia also announced the appointment of Mr. Frederic Porte, President of Medipress Management Inc., as a new director of the Company. Dr. Bernard Coupal, President of T2/C2 and a director of Ambrilia since 1999, resigned.
